Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Parkinson's disease Stories

2014-03-21 23:01:42

Many living with Parkinson’s Disease are at their wit’s end as they face their medication’s dosage limits and there are no longer any measurable differences in their symptoms. When typical Parkinson’s Treatment paths are completely exhausted, patients begin to turn to alternative methods to control their symptoms so that they can regain some semblance of daily living without discomfort (or near as much). (PRWEB) March 21, 2014 Parkinson’s Disease is a degenerative disorder of...

2014-03-18 23:03:24

Transparency Market Research Report published "Deep Brain Stimulation Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019" to its database. Browse the report with Full TOC at http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html. Albany, New York (PRWEB) March 18, 2014 According to a new market report published by Transparency Market Research "Deep Brain Stimulation Devices Market for Parkinson's...

2014-03-18 08:31:38

ALBANY, New York, March 18, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Deep Brain Stimulation Devices Market for Parkinson's Disease (North America, Europe, Asia-Pacific and Latin America)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global deep brain stimulation devices market was valued at USD 4.5 billion in 2012 and is expected to grow at a CAGR of 11.0% from 2013 to 2019, to...

2014-03-13 16:27:32

Research Areas Chosen by People with Parkinson's through PDF Community Choice Research Awards NEW YORK, March 13, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Disease Foundation® (PDF®) is pleased to announce $30,000 in funding to address two disabling, yet under-recognized symptoms of Parkinson's disease - fatigue and gastrointestinal dysfunction - through its first Community Choice Research Awards. The patient community identified these two areas as priorities for scientific...

2014-03-11 08:29:26

REHOVOT, Israel, March 11, 2014 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease....

2014-03-10 12:26:00

LBD, the Second Most Common Progressive Dementia after Alzheimer's ATLANTA, March 10, 2014 /PRNewswire-USNewswire/ -- Today, for Brain Awareness Week, March 10-16, 2014, the Lewy Body Dementia Association (LBDA), calls attention to critical differences in dementia-causing disorders that may have potentially life-saving implications. Lewy body dementia (LBD) is the most misdiagnosed form of dementia and, following Alzheimer's disease, is the second most common cause of progressive...

2014-03-07 12:26:20

Volunteer Network Has Track Record of Improving Trial Recruitment, Removing Research Roadblocks NEW YORK, March 7, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Disease Foundation® (PDF®) invites research professionals within industry, academia and government, to partner with its trained patient advocates to bring about better treatments for Parkinson's disease. This week, PDF welcomes new members to its national network, which now includes more than 230 Research Advocates whose...

2014-03-06 23:29:35

Phoenix Research Labs, Inc., Neuropore Therapies, and UC San Diego today announced breakthrough study results from an industry-academia collaborative effort demonstrating the utility and relevance of Phoenix’s retinal imaging technology as a non-invasive and effective method to evaluate and track the progression of neurodegenerative changes in animal models of Parkinson’s disease. Pleasanton, CA (PRWEB) March 06, 2014 Phoenix Research Labs, Inc., Neuropore Therapies, and UC San Diego...

2014-03-05 23:02:30

Governor of Connecticut acknowledges the need for greater awareness of the neurological condition that affects 10 million Americans. Lenexa, Kansas (PRWEB) March 05, 2014 As part of National Essential Tremor Awareness Month, the International Essential Tremor Foundation (IETF) is delighted to announce that Dannel Malloy, governor of Conn., has officially proclaimed the state’s support of Essential Tremor Awareness Month; joining others nationwide in recognizing the need to learn more...

2014-03-05 12:26:28

VALLEY VIEW, Ohio, March 5, 2014 /PRNewswire/ -- Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company's fourth in the past eight months focused on technology for Parkinson's disease diagnostics and treatment. This particular application covers a device and method of measuring Parkinson's motor symptoms such as tremor, bradykinesia, rigidity, and gait abnormalities or therapy side effects such as...